Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

NCT07031063 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

124

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infection
Metabolic Syndrome
Antiretroviral Treatment

Interventions

DRUG: DTG/3TC
DRUG: Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

Sponsor

Instituto Mexicano del Seguro Social